{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:51:51Z","timestamp":1794243111863,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Fund Project of Zhejiang Medical Association","award":["(2021ZYC-Z05)"],"award-info":[{"award-number":["(2021ZYC-Z05)"]}]},{"name":"\"Great Medical Sincerity\" cancer prevention and treatment research and academic exchange public welfare program"},{"name":"Hangzhou Agricultural and social Development Research Project","award":["(2020ZDSJ0552)"],"award-info":[{"award-number":["(2020ZDSJ0552)"]}]},{"name":"Zhejiang Province Health Department Project","award":["(2022KY101)"],"award-info":[{"award-number":["(2022KY101)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13801-0","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:36:00Z","timestamp":1741955760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Zihao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"13801_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"13801_CR2","doi-asserted-by":"publisher","first-page":"1177085","DOI":"10.3389\/fimmu.2023.1177085","volume":"14","author":"M Jiang","year":"2023","unstructured":"Jiang M, Hu Y, Lin G, Chen C, Li H. Radiotherapy combined with immune checkpoint inhibitors in locally advanced\/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions. Front Immunol. 2023;14:1177085. https:\/\/doi.org\/10.3389\/fimmu.2023.1177085.","journal-title":"Front Immunol"},{"key":"13801_CR3","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/jco.20.03697","volume":"39","author":"M Hulshof","year":"2021","unstructured":"Hulshof M, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021;39:2816\u201324. https:\/\/doi.org\/10.1200\/jco.20.03697.","journal-title":"J Clin Oncol"},{"key":"13801_CR4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1158\/1078-0432.Ccr-21-3843","volume":"28","author":"Y Xu","year":"2022","unstructured":"Xu Y, Dong B, Zhu W, et al. A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2022;28:1792\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3843.","journal-title":"Clin Cancer Res"},{"key":"13801_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/jco.18.02122","volume":"37","author":"Y Chen","year":"2019","unstructured":"Chen Y, Ye J, Zhu Z, et al. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. J Clin Oncol. 2019;37:1695\u2013703. https:\/\/doi.org\/10.1200\/jco.18.02122.","journal-title":"J Clin Oncol"},{"key":"13801_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(21)01234-4.","journal-title":"Lancet"},{"key":"13801_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326:916\u201325. https:\/\/doi.org\/10.1001\/jama.2021.12836.","journal-title":"JAMA"},{"key":"13801_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286\u201394. https:\/\/doi.org\/10.1016\/j.trecan.2016.05.002.","journal-title":"Trends Cancer"},{"key":"13801_CR9","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.Ccr-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov A, Baker J, Mueller AM, et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res. 2015;21:3727\u201339. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2824.","journal-title":"Clin Cancer Res"},{"key":"13801_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.Can-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488\u201396. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-2820.","journal-title":"Cancer Res"},{"key":"13801_CR11","doi-asserted-by":"publisher","unstructured":"Wang L, Lynch C, Pitroda SP, Piffk\u00f3 A, Yang K, Huser AK, Liang HL, Weichselbaum RR. Radiotherapy and immunology. J Exp Med. 2024;221.\u00a0https:\/\/doi.org\/10.1084\/jem.20232101.","DOI":"10.1084\/jem.20232101"},{"key":"13801_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/jci67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687\u201395. https:\/\/doi.org\/10.1172\/jci67313.","journal-title":"J Clin Invest"},{"key":"13801_CR13","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.Can-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458\u201368. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-1258.","journal-title":"Cancer Res"},{"key":"13801_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134. https:\/\/doi.org\/10.1038\/nature21724.","journal-title":"Nature"},{"key":"13801_CR15","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/jci96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng X, Fang Z, Liu X, et al. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest. 2018;128:2104\u201315. https:\/\/doi.org\/10.1172\/jci96582.","journal-title":"J Clin Invest"},{"key":"13801_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2018-0049","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Lin X, Luo Y, et al. \u03b1-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8(+) T-cell infiltration. Immunotherapy. 2019;11:101\u201318. https:\/\/doi.org\/10.2217\/imt-2018-0049.","journal-title":"Immunotherapy"},{"key":"13801_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","volume":"12","author":"X Gong","year":"2017","unstructured":"Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, Zhou C. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12:1085\u201397. https:\/\/doi.org\/10.1016\/j.jtho.2017.04.014.","journal-title":"J Thorac Oncol"},{"key":"13801_CR18","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516\u201323. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7516.","journal-title":"J Immunol"},{"key":"13801_CR19","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.Ccr-18-1038","volume":"24","author":"A Oweida","year":"2018","unstructured":"Oweida A, Hararah MK, Phan A, et al. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018;24:5368\u201380. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1038.","journal-title":"Clin Cancer Res"},{"key":"13801_CR20","doi-asserted-by":"publisher","first-page":"e1356153","DOI":"10.1080\/2162402X.2017.1356153","volume":"6","author":"A Oweida","year":"2017","unstructured":"Oweida A, Lennon S, Calame D, et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017;6:e1356153.","journal-title":"Oncoimmunology"},{"key":"13801_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","volume":"7","author":"SO Dudzinski","year":"2019","unstructured":"Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J Immunother Cancer. 2019;7:218. https:\/\/doi.org\/10.1186\/s40425-019-0704-z.","journal-title":"J Immunother Cancer"},{"key":"13801_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41416-020-0956-x","volume":"123","author":"Y Philippou","year":"2020","unstructured":"Philippou Y, Sjoberg HT, Murphy E, et al. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br J Cancer. 2020;123:1089\u2013100. https:\/\/doi.org\/10.1038\/s41416-020-0956-x.","journal-title":"Br J Cancer"},{"key":"13801_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","volume":"9","author":"A Azad","year":"2017","unstructured":"Azad A, Yin Lim S, D\u2019Costa Z, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9:167\u201380. https:\/\/doi.org\/10.15252\/emmm.201606674.","journal-title":"EMBO Mol Med"},{"key":"13801_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1258\/002367796780739871","volume":"30","author":"B Close","year":"1996","unstructured":"Close B, Banister K, Baumans V, et al. Recommendations for euthanasia of experimental animals: Part 1. DGXI of the European Commission. Lab Anim. 1996;30:293\u2013316. https:\/\/doi.org\/10.1258\/002367796780739871.","journal-title":"Lab Anim"},{"key":"13801_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.30802\/aalas-jaalas-19-000081","volume":"59","author":"D Pang","year":"2020","unstructured":"Pang D, Laferriere C. Review of Intraperitoneal Injection of Sodium Pentobarbital as a Method of Euthanasia in Laboratory Rodents. J Am Assoc Lab Anim Sci. 2020;59:346. https:\/\/doi.org\/10.30802\/aalas-jaalas-19-000081.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"13801_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1535-7163.Mct-18-0986","volume":"19","author":"A Rompr\u00e9-Brodeur","year":"2020","unstructured":"Rompr\u00e9-Brodeur A, Shinde-Jadhav S, Ayoub M, Piccirillo CA, Seuntjens J, Brimo F, Mansure JJ, Kassouf W. PD-1\/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer. In Situ and Abscopal Effects. Mol Cancer Ther. 2020;19:211\u201320. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0986.","journal-title":"Mol Cancer Ther"},{"key":"13801_CR27","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132\u20139. https:\/\/doi.org\/10.4049\/jimmunol.180.5.3132.","journal-title":"J Immunol"},{"key":"13801_CR28","first-page":"833","volume":"53","author":"TM Tuttle","year":"1993","unstructured":"Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. gamma-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res. 1993;53:833\u20139.","journal-title":"Cancer Res"},{"key":"13801_CR29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin N. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Front Immunol. 2020;11:976. https:\/\/doi.org\/10.3389\/fimmu.2020.00976.","journal-title":"Front Immunol"},{"key":"13801_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18:219\u201334. https:\/\/doi.org\/10.1038\/s41573-018-0011-2.","journal-title":"Nat Rev Drug Discov"},{"key":"13801_CR31","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol. 2018;9:2061. https:\/\/doi.org\/10.3389\/fimmu.2018.02061.","journal-title":"Front Immunol"},{"key":"13801_CR32","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ajpath.2013.02.041","volume":"182","author":"SA Gerber","year":"2013","unstructured":"Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-\u03b3 mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol. 2013;182:2345\u201354. https:\/\/doi.org\/10.1016\/j.ajpath.2013.02.041.","journal-title":"Am J Pathol"},{"key":"13801_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/cgt.2014.60","volume":"21","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther. 2014;21:532\u201341. https:\/\/doi.org\/10.1038\/cgt.2014.60.","journal-title":"Cancer Gene Ther"},{"key":"13801_CR34","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208:2005\u201316. https:\/\/doi.org\/10.1084\/jem.20101159.","journal-title":"J Exp Med"},{"key":"13801_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot N, Roberti MP, Enot DP, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017;8:592. https:\/\/doi.org\/10.1038\/s41467-017-00608-2.","journal-title":"Nat Commun"},{"key":"13801_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137. https:\/\/doi.org\/10.1038\/nature14292.","journal-title":"Nature"},{"key":"13801_CR37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.Can-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y, Nickles D, Cubas R. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Res. 2019;79:1493\u2013506. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3208.","journal-title":"Cancer Res"},{"key":"13801_CR38","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1053\/j.gastro.2016.02.070","volume":"150","author":"L Seifert","year":"2016","unstructured":"Seifert L, Werba G, Tiwari S, et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659-72.e5. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.070.","journal-title":"Gastroenterology"},{"key":"13801_CR39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/2326-6066.Cir-17-0537","volume":"6","author":"GP Hartley","year":"2018","unstructured":"Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunol Res. 2018;6:1260\u201373. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0537.","journal-title":"Cancer Immunol Res"},{"key":"13801_CR40","doi-asserted-by":"publisher","unstructured":"Jones KI, Tiersma J, Yuzhalin AE, Gordon-Weeks AN, Buzzelli J, Im JH, Muschel RJ. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med. 2018;10.\u00a0https:\/\/doi.org\/10.15252\/emmm.201809342.","DOI":"10.15252\/emmm.201809342"},{"key":"13801_CR41","doi-asserted-by":"publisher","unstructured":"Sheng H, Huang Y, Xiao Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. 2020;8.\u00a0https:\/\/doi.org\/10.1136\/jitc-2019-000340.","DOI":"10.1136\/jitc-2019-000340"},{"key":"13801_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s40425-019-0698-6","volume":"7","author":"JM Newton","year":"2019","unstructured":"Newton JM, Hanoteau A, Liu HC, et al. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. J Immunother Cancer. 2019;7:216. https:\/\/doi.org\/10.1186\/s40425-019-0698-6.","journal-title":"J Immunother Cancer"},{"key":"13801_CR43","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105:15016\u201321. https:\/\/doi.org\/10.1073\/pnas.0801497105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13801_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.Cir-21-0515","volume":"10","author":"N Budimir","year":"2022","unstructured":"Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1\/PD-L1 Immune Checkpoint Blockade. Cancer Immunol Res. 2022;10:146\u201353. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0515.","journal-title":"Cancer Immunol Res"},{"key":"13801_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/intimm\/dxac038","volume":"34","author":"S Ando","year":"2022","unstructured":"Ando S, Araki K. CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. Int Immunol. 2022;34:571\u20137. https:\/\/doi.org\/10.1093\/intimm\/dxac038.","journal-title":"Int Immunol"},{"key":"13801_CR46","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","volume":"54","author":"BS Hanna","year":"2021","unstructured":"Hanna BS, Lla\u00f3-Cid L, Iskar M, et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity. Immunity. 2021;54:2825-41.e10. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.004.","journal-title":"Immunity"},{"key":"13801_CR47","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cac2.12348","volume":"42","author":"Z Liu","year":"2022","unstructured":"Liu Z, Yu Z, Chen D, et al. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy. Cancer Commun (Lond). 2022;42:971\u201386. https:\/\/doi.org\/10.1002\/cac2.12348.","journal-title":"Cancer Commun (Lond)"},{"key":"13801_CR48","doi-asserted-by":"publisher","unstructured":"Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight. 2018;3.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.124507.","DOI":"10.1172\/jci.insight.124507"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13801-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:36:17Z","timestamp":1741955777000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13801"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13801-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC 20010652), Zhejiang Center of Laboratory Animals(ZJCLA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}